RaQualia Pharma Inc. (TYO:4579)
574.00
-1.00 (-0.17%)
Aug 27, 2026, 11:29 AM JST
RaQualia Pharma Revenue
RaQualia Pharma had revenue of 653.01M JPY in the quarter ending June 30, 2026, with 14.64% growth. This brings the company's revenue in the last twelve months to 3.90B, up 20.67% year-over-year. In the year 2025, RaQualia Pharma had annual revenue of 3.98B with 28.07% growth.
Revenue (ttm)
3.90B
Revenue Growth
+20.67%
P/S Ratio
3.84
Revenue / Employee
45.87M
Employees
85
Market Cap
14.97B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.98B | 872.00M | 28.07% |
| Dec 31, 2024 | 3.11B | 1.21B | 63.44% |
| Dec 31, 2023 | 1.90B | -1.02B | -34.85% |
| Dec 31, 2022 | 2.92B | 142.00M | 5.12% |
| Dec 31, 2021 | 2.78B | 1.67B | 150.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ReproCELL | 2.30B |
| Immuno-Biological Laboratories | 1.08B |
| AnGes | 962.00M |
| SUSMED,Inc. | 497.00M |
| Stella Pharma | 323.00M |
| Nano Holdings | 202.00M |
| CellSeed | 161.00M |
| Renascience | 68.00M |